NEW YORK (AP) — In a story September 29, 2020, which included information about Myovant Sciences’ potential prostate cancer drug, The Associated Press erroneously reported that the drug failed to meet multiple goals in a study. The drug failed to meet one of its goals within a broader late-stage study.
Before you consider Medigus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medigus wasn't on the list.
While Medigus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.
Get This Free Report